Suppr超能文献

T1/T2期乳腺癌强化保乳治疗(包括高剂量大体积组织间近距离放疗推量,LDR/HDR)的长期(10年)结果。

Long-term results (10 years) of intensive breast conserving therapy including a high-dose and large-volume interstitial brachytherapy boost (LDR/HDR) for T1/T2 breast cancer.

作者信息

Resch Alexandra, Pötter Richard, Van Limbergen Erik, Biber Eva, Klein Tanja, Fellner Claudia, Handl-Zeller Leonore, Langbauer Gudrun, Schürer-Waldheim Helmut, Staffen Alfred, Jakesz Raimund, Kubista Ernst, Lehr Stephan, Seitz Wolfgang

机构信息

Department of Radiotherapy and Radiobiology, Vienna University, Medical School, General Hospital of Vienna, Währinger Gürtel 18-22, Vienna, Austria.

出版信息

Radiother Oncol. 2002 Apr;63(1):47-58. doi: 10.1016/s0167-8140(02)00022-1.

Abstract

BACKGROUND AND PURPOSE

During the past 15 years many retrospective studies and prospective randomized trials have been published supporting the use of breast conserving treatment (BCT) including surgery and radiotherapy. However, there are still many controversies on the necessary amount of resection, the width of the resection margins and the optimal radiation technique, dose and volume, in particular of the boost. In this retrospective study a large cohort of 410 women with early breast cancer treated with BCT including an interstitial brachytherapy (BT) boost is evaluated after a long follow-up period.

MATERIAL AND METHODS

In order to clarify the impact of the different treatment-related factors on local control, these were carefully discriminated, based on widely accepted classification and reporting systems for surgery as well as for radiotherapy. The surgical approach was classified according to EORTC criteria and a high rate of quadrantectomies (60%) was found. Dose and volume of interstitial BT is reported according to recommendations of ICRU 58, and reveals a significant radiation dose and volume: minimum target dose, mean central dose (MCD) and '85% of MCD' for low-dose rate (LDR) BT was mean 20, 28 and 24 Gy, for high-dose rate (HDR) BT it was mean '10, 15 and 13 Gy, respectively; the treated volume was 104 cc for LDR BT and 83 cc for HDR BT.

RESULTS

The actuarial rates for overall survival, disease-free survival and disease-specific survival were 97, 90 and 98% at 5 years and 85, 79 and 92% at 10 years. There have been only 16 breast recurrences in 410 treated patients resulting in a 5- and 10-year actuarial local recurrence rate of 2 and 3.9%, respectively; six recurrences (1.5%) were in the original quadrant. Except age and menopausal status, all tumour- and patient-related risk factors had no significant impact on local control.

CONCLUSIONS

Our data confirm that intensive BCT leads to excellent long-term results in terms of local control, masking classical risk factors. This high-dose and large-volume interstitial BT seems to be superior to classical BCT without BT.

摘要

背景与目的

在过去15年中,许多回顾性研究和前瞻性随机试验相继发表,支持采用包括手术和放疗在内的保乳治疗(BCT)。然而,在切除的必要范围、切缘宽度以及最佳放疗技术、剂量和体积(尤其是追加剂量)方面仍存在诸多争议。在这项回顾性研究中,对一大群410例接受BCT(包括组织间近距离放疗(BT)追加剂量)治疗的早期乳腺癌女性患者进行了长期随访评估。

材料与方法

为阐明不同治疗相关因素对局部控制的影响,基于广泛接受的手术及放疗分类和报告系统,对这些因素进行了仔细区分。手术方式根据欧洲癌症研究与治疗组织(EORTC)标准分类,发现象限切除术的比例较高(60%)。组织间BT的剂量和体积根据国际辐射单位与测量委员会(ICRU)58号报告的建议进行报告,显示出显著的辐射剂量和体积:低剂量率(LDR)BT的最小靶剂量、平均中心剂量(MCD)和“MCD的85%”分别平均为20、28和24 Gy,高剂量率(HDR)BT分别平均为10、15和13 Gy;LDR BT的治疗体积为104 cc,HDR BT为83 cc。

结果

5年时总生存、无病生存和疾病特异性生存的精算率分别为97%、90%和98%,10年时分别为85%、79%和92%。410例接受治疗的患者中仅出现16例乳腺复发,5年和10年的精算局部复发率分别为2%和3.9%;6例复发(1.5%)发生在原象限。除年龄和绝经状态外,所有肿瘤及患者相关危险因素对局部控制均无显著影响。

结论

我们的数据证实,强化BCT在局部控制方面可带来优异的长期效果,掩盖了经典危险因素。这种高剂量和大体积的组织间BT似乎优于未采用BT的经典BCT。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验